IP Library Granted Patent US 10,174,094
Granted Patent B2
US 10,174,094 · App. 15/045,906 · Granted Jan 8, 2019

Reversible covalent linkage of functional molecules

Inventors: Mark Smith (London, GB); Stephen Caddick (London, GB); James Baker (London, GB); Vijay Chudasama (London, GB)
Assignee: UCL Business Plc
C07K14/655A61K47/551A61K47/60A61K47/62A61K49/0017C07D207/416C07D207/456C07D209/52C07K14/435G01N33/58Y02P20/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,174,094
App. No.
15/045,906
Granted
Jan 8, 2019
Kind
B2
Abstract

The present invention relates to the use of a compound containing a moiety of formula (I) as a reagent for linking a compound of formula R 1 —H which comprises a first functional moiety of formula F 1 to a second functional moiety of formula F 2 wherein X, X′, Y, R 1 , F 1 and F 2 are as defined herein. The present invention also provides related processes and products. The present invention is useful for creating functional conjugate compounds, and specifically conjugates in which at least one of the constituent molecules carries a thiol group.

Claims (11)

1. A compound of formula (IIIa)

wherein:

R 1 is an antibody or antibody fragment that is capable of binding to a specific antigen via an epitope on the antigen, said antibody or antibody fragment containing a first cysteine residue and a second cysteine residue;

R 1 is attached at the 2-position in the compound of formula (IIIa) by a thiol bond —S— which corresponds to the thiol group in said first cysteine residue;

R 1 is attached at the 3-position in the compound of formula (IIIa) by a thiol bond —S— which corresponds to the thiol group in said second cysteine residue;

F 2 is a drug; and

L represents a linker group.

2. A compound according to claim 1 , wherein the first cysteine residue of R 1 and the second cysteine residue of R 1 in the compound of formula (IIIa) are derived from an internal disulfide bridge formed in the antibody or antibody fragment.

3. A compound according to claim 1 , wherein R 1 is an antibody.

4. A compound according to claim 1 , wherein the drug is a cytotoxic agent.

5. A compound according to claim 3 , wherein F 2 is a cytotoxic agent.

Assignments (2)
CHANGE OF NAME Recorded Dec 11, 2019
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 051247/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2018
From: SMITH, MARK; CADDICK, STEPHEN; BAKER, JAMES; CHUDASAMA, VIJAY
To: UCL BUSINESS PLC
Reel/Frame 046240/0970 →
Priority Claims (3)
GB 0913965.0 · Aug 10, 2009 · national
GB 0913967.6 · Aug 10, 2009 · national
GB 0914321.5 · Aug 14, 2009 · national
Continuity (2)
Continuation 13389625
Related Publication 20160176942A1 · Jun 23, 2016